Table 2.
Single-armed phase II clinical trials evaluating second-line single-agent chemotherapy in advanced pancreatic cancer
| Study | Treatment | No of patients* | ECOG 0–1 (%)/KPS 90–100 (%) | Metastatic disease (%) | Response rate | Median survival |
|---|---|---|---|---|---|---|
| Hosein et al22 | Nab-paclitaxel 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle | 19 | 79 | 95 | CR 0%; PR 5%; SD 32% | OS 7.3 months; PFS 1.7 months |
| Ko et al20 | Nanoliposomal irinotecan 120 mg/m2 every 3 weeks | 40 | 60 | 100 | PR 7.5%; SD 42.5%; PD 25.0% | OS 5.2 months; PFS 2.4 months |
| Sudo et al18 | S-1 40 mg/m2 orally, twice a day for 4 weeks on a 6-week cycle | 21 | 71.4 | 95 | PR 9.5%; SD 43% | OS 6.3 months; PFS 4.1 months |
| Yi et al19 | Irinotecan 150 mg/m2 every 2 weeks | 33 | 94 | 100 | PR 9%; SD 39% | OS 6.6 months; PFS 2.0 months |
| Morizane et al17 | S-1 40 mg/m2 orally, twice a day for 4 weeks on a 6-week cycle | 40 | 90 | 100 | CR 0%; PR 15%; SD 43%; PD 38% | OS 4.5 months; PFS 2.0 months |
| Boeck et al21 | Capecitabine 1,250 mg/m2 orally, twice a day for 2 weeks on a 3-week cycle | 39 | 51 | 97 | PR 0; SD 39%; PD 31% | OS 7.6 months |
| Boeck et al16 | Pemetrexed 500 mg/m2 every 3 weeks | 52 | 94.2 | 88.5 | PR 3.8%; SD 19.2%; PD 59.6% | OS 20 weeks |
| Androulakis et al15 | Oxaliplatin 130 mg/m2 every 3 weeks | 18 | 72 | 72 | CR 0%; PR 0%; SD 16.7% | OS 3.5 months |
Notes:
*
All patients were previously treated with first-line gemcitabine monotherapy or gemcitabine-based combination therapy.
Abbreviations: CR, complete response; ECOG, Eastern Oncology Cooperative Group; KPS, Karnofsky performance status; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; S-1, tegafur/gimeracil/oteracil.